Brind.

The LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc., is currently undergoing FDA review for clearance, with its patent expanding potential applications.

4 reports, 4 independent Updated 00:00
Still developing Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

The LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc., is currently undergoing FDA review for clearance, with its patent expanding potential applications.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA grants clearance for a new robotic surgery system targeting breast cancer.1 source
  2. FDA reviewing clearance for Microbot Medical's LIBERTY robotic system.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • vox.com
  • ZacksMicrobot Shares Rise as New U.S. Patent Expands LIBERTY System Market Microbot Medical Inc. MBOT has been granted a new U.S. patent that broadens the potential applications of its LIBERTY Endovascula
  • GlobeNewswireMicrobot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents gr
  • Medical Device NetworkMicrobot Medical secures grant for endovascular robotic system Microbot Medical has secured a non-dilutive NIS2.15m (around $630,000) grant from the Israel Innovation Authority (IIA) to bolster its m